Evidence map›Paper›PMID 42826203›Full record

ArticleScience advances2026

Macrophage-supported metabolic adaptation drives tumor survival under nutrient stress.

Nancy T Santiappillai, Andrew Cho, Georg Verch, Ana C Codo, Achuth Nair, Ya-Ting Wang, Allie Lipshutz, Celia Martínez de la Torre, Eric Minwei Liu, Marjan Berishaj and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nancy T SantiappillaiCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9797-559X
Andrew ChoCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5396-5354
Georg VerchCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0002-9088-0111
Ana C CodoImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9036-5772
Achuth NairImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0003-2933-3490
Ya-Ting WangImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1101-5438
Allie LipshutzImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-1786-7300
Celia Martínez de la TorreCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5088-3839
Eric Minwei LiuComputational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3594-6678
Marjan BerishajCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alissa J TrzeciakImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4518-0098
Zhaoquan WangImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8227-0941
Michelle SaoiThe Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7678-6239
Waleska Saitz RojasImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-0186-1980
Justin R CrossThe Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ed ReznikComputational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6511-5947
Justin S A PerryImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4063-6524
Kayvan R KeshariCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5181-8035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) develops in hypoxic, nutrient-limited tumors enriched with macrophages and cell death. We show that metabolically distinct TNBCs differentially exploit macrophage-derived nutrients, influencing tumor growth and therapeutic response. Prolonged hypoxia reprogrammed mouse and human macrophages, enabling them to release metabolites that rescued the growth of select TNBC cell lines during glutamine deprivation or glutamine metabolism inhibition. Hypoxic macrophages reduced glutamine consumption, increased arginine utilization, and secreted higher levels of ornithine, an intermediate of arginine metabolism. Exogenous ornithine, but not arginine, restored the growth of responsive TNBC cells. Mechanistically, TNBC cells diverted ornithine into proline biosynthesis, supporting oxidative pentose phosphate pathway activity. In vivo, depletion of tumor-associated myeloid cells reduced tumor growth and impaired proline synthesis in glutaminase inhibitor-resistant TNBC. These findings identify hypoxia-driven metabolic cross-talk between macrophages and TNBC cells, revealing ornithine-dependent proline metabolism as a mechanism by which macrophages sustain tumor growth under nutrient stress and contribute to resistance to glutamine-targeted therapies.

Indexed as

MacrophagesNutrientsStress, PhysiologicalTriple Negative Breast NeoplasmsAnimalsArginineCell Line, TumorCell SurvivalFemaleGlutamineHumansMetabolic ReprogrammingMiceOrnithineProlineArginineGlutamineOrnithineProline

Identifiers

PMID42826203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.